Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01143038
Other study ID # 20080435
Secondary ID 2010-019987-35
Status Completed
Phase Phase 2
First received
Last updated
Start date November 30, 2010
Est. completion date December 26, 2013

Study information

Verified date September 2022
Source Amgen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to describe the number of months with a platelet response over a 12 month treatment period and to describe ITP remission rates in adults with ITP receiving romiplostim.


Description:

The study includes a 4-week screening period, a 12-month romiplostim treatment period, and a romiplostim dose-tapering period. During the 12-month treatment period romiplostim doses could be increased or decreased to maintain a platelet count between ≥ 50 x 10^9/L and ≤ 200 x 10^9/L. Participants who dose reduce such that they no longer require treatment with romiplostim during the 12-month treatment period will continue with all required study procedures up to 12 months and will be monitored for ITP remission for at least 6 months. At the completion of the 12-month treatment period, participants receiving only romiplostim and with a platelet count ≥ 50 x 10^9/L will enter the tapering period, during which the romiplostim dose will be decreased by 1 µg/kg every 2 weeks, for up to 19 weeks. If a participant maintains a platelet count of ≥ 50 x 10^9/L in the absence of romiplostim and all medications for ITP (concomitant or rescue), the participant will be followed for at least 6 months to confirm the incidence of ITP remission. If a participant's platelet count falls below 50 x 10^9/L and the participant has tapered off treatment with romiplostim, the participant will enter the stabilization period and reinitiate romiplostim for up to 8 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 75
Est. completion date December 26, 2013
Est. primary completion date September 20, 2013
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subject has been diagnosed with primary ITP according to the American Society of Hematology (ASH) guidelines (George et al, 1996) and previously received only 1st line therapies. First line therapy is defined as corticosteroids, immunoglobulin G (IVIG), anti-D and vinca alkaloids (used for the treatment of ITP related thrombocytopenia only). A platelet transfusion at any time during the six month period since the original diagnosis would not exclude the subject from study participation - Initial diagnosis of primary ITP within 6 months of enrollment - Age = 18 years at screening - A single platelet count = 30 x 10?/L at any time during the screening period - Subject or subject's legally acceptable representative has provided informed consent Exclusion Criteria: - Known history of a bone marrow stem cell disorder - Surgical resection of the spleen - Subject has a history of cancer or current malignancy other than basal cell carcinoma or cervical cancer in-situ with active treatment or disease within 5 years of screening - Known history of congenital thrombocytopenia - Known history of hepatitis B, hepatitis C, or human immunodeficiency virus - Positive H. pylori by urea breath test or stool antigen test at screening - Known history of systemic lupus erythematosus, Evans syndrome, or autoimmune neutropenia - Known history of antiphospholipid antibody syndrome or positive for lupus anticoagulant - Known history of disseminated intravascular coagulation, hemolytic uremic syndrome, or thrombotic thrombocytopenic purpura - Previous history of recurrent venous thromboembolism or thrombotic events or an occurrence within 5 years of enrollment. - Previous use of romiplostim, pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), eltrombopag, recombinant human thrombopoietin (rHuTPO) or any platelet producing agent - Rituximab (for any indication) or mercaptopurine (6-MP) or anticipated use during the time of the proposed study - All hematopoietic growth factors including interleukin-11 (IL-11) (oprelvekin) within 4 weeks before the screening visit - Alkylating agents use at any time before or during the screening visit or anticipated during the time of the proposed study - Known hypersensitivity to any recombinant E. coli-derived product (eg, Infergen, Neupogen, Somatropin, and Actimmune) - Currently enrolled in another investigational device or drug study, or less than 30 days since ending another investigational device or drug study(s), or receiving other investigational agent(s) - Subject will have any other investigational procedures performed while enrolled in this clinical study - Subject is pregnant or breast feeding, or planning to become pregnant within 5 weeks after the end of treatment - Female subject of child bearing potential is not willing to use, in combination with her partner, highly effective contraception during treatment and for 4 weeks after the end of treatment - Subject has previously enrolled into a romiplostim study - Subject will not be available for protocol required study visits, to the best of the subject's and investigator's knowledge - Subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or to comply with all required study procedures

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Romiplostim
Romiplostim will be administered weekly by subcutaneous injection

Locations

Country Name City State
Australia Research Site Adelaide South Australia
Australia Research Site Randwick New South Wales
Australia Research Site Woolloongabba Queensland
Czechia Research Site Brno
Czechia Research Site Ostrava-Poruba
Czechia Research Site Praha 10
Czechia Research Site Praha 2
Czechia Research Site Praha 2
France Research Site Bondy Cedex
France Research Site Créteil Cedex
France Research Site Dijon
France Research Site Pessac Cedex
France Research Site Toulouse Cedex 9
Germany Research Site Dresden
Germany Research Site Duisburg
Germany Research Site Düsseldorf
Germany Research Site Köln
Italy Research Site Bari
Italy Research Site Catania
Italy Research Site Monza (MB)
Italy Research Site Napoli
Italy Research Site Novara
Italy Research Site Roma
Italy Research Site San Giovanni Rotondo FG
Italy Research Site Vicenza
Poland Research Site Gdansk
Poland Research Site Katowice
Poland Research Site Lublin
Poland Research Site Poznan
Poland Research Site Wroclaw
Spain Research Site A Coruña Galicia
Spain Research Site Alcorcon Madrid
Spain Research Site Barcelona Cataluña
Spain Research Site Majadahonda Madrid
Spain Research Site Málaga Andalucía
United Kingdom Research Site Coventry
United Kingdom Research Site Leeds
United Kingdom Research Site London
United Kingdom Research Site London
United Kingdom Research Site Oxford
United States Research Site Anaheim California
United States Research Site Bethesda Maryland
United States Research Site Boynton Beach Florida
United States Research Site Charleston South Carolina
United States Research Site Hickory North Carolina
United States Research Site Orange California
United States Research Site Philadelphia Pennsylvania
United States Research Site Richlands Virginia

Sponsors (1)

Lead Sponsor Collaborator
Amgen

Countries where clinical trial is conducted

United States,  Australia,  Czechia,  France,  Germany,  Italy,  Poland,  Spain,  United Kingdom, 

References & Publications (4)

Cines DB, Wasser J, Rodeghiero F, Chong BH, Steurer M, Provan D, Lyons R, Garcia-Chavez J, Carpenter N, Wang X, Eisen M. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia. Haematologica. 2017 Aug;102(8):1342-1351. doi: 10.3324/haematol.2016.161968. Epub 2017 Apr 14. — View Citation

Kuter DJ, Arnold DM, Rodeghiero F, Janssens A, Selleslag D, Bird R, Newland A, Mayer J, Wang K, Olie R. Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials. Am J Hematol. 2020 Jun;95(6):643-651. doi: 10.1002/ajh.25776. Epub 2020 Mar 21. — View Citation

Kuter DJ, Newland A, Chong BH, Rodeghiero F, Romero MT, Pabinger I, Chen Y, Wang K, Mehta B, Eisen M. Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies. Br J Haematol. 2019 May;185(3):503-513. doi: 10.1111/bjh.15803. Epub 2019 Feb 21. — View Citation

Newland A, Godeau B, Priego V, Viallard JF, López Fernández MF, Orejudos A, Eisen M. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study. Br J Haematol. 2016 Jan;172(2):262-73. doi: 10.1111/bjh.13827. Epub 2015 Nov 5. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Months With Platelet Response During the 12-Month Treatment Period The primary endpoint was the number of months a participant achieved a platelet response during the 12-month treatment period. A platelet response for any 1 month was defined as the median of platelet counts measured in the month = 50 x 10^9/L. Platelet counts within 4 weeks following a rescue medication use or following splenectomy were considered non-response. Months without any platelet count measurement were considered as months with no platelet response. 12 months
Secondary Percentage of Participants With ITP Remission ITP remission was defined as maintaining every platelet count = 50 x 10^9/L for at least 6 months in the absence of romiplostim and any other therapies to treat ITP. Up to 24 months
Secondary Percentage of Participants With Splenectomy During the 12-month Treatment Period If treatment with romiplostim was deemed ineffective or intolerable by the investigator, a splenectomy may have been performed. 12 months
Secondary Number of Participants With Adverse Events An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant. The event does not necessarily have a causal relationship with study treatment. A serious adverse event is defined as an adverse event that meets at least one of the following serious criteria: • fatal • life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • congenital anomaly/birth defect • other significant medical hazard. Whether an adverse event was treatment-related (TRAE) or not was determined by investigator. From first dose date of romiplostim to end of study (up to 24 months).
Secondary Number of Participants Who Developed Antibodies to Romiplostim The number of participants who developed antibody formation (defined as negative at baseline and positive at post-baseline, transient or persistent) to romiplostim, endogenous thrombopoietin (eTPO), and thrombopoietin mimetic peptide (TMP, the peptide component of romiplostim) was summarized. Baseline and at end of treatment (based on response to treatment, this could occur between 12 months and approximately 18 months)
See also
  Status Clinical Trial Phase
Completed NCT05220878 - Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP Phase 3
Completed NCT00451594 - High Dose Dexamethasone Vs. Conventional Dose Prednisolone in Adult ITP Phase 3
Withdrawn NCT01276561 - Single Incision Versus Standard Laparoscopic Splenectomy N/A
Completed NCT01713855 - Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura N/A
Recruiting NCT03465020 - Investigation on a Dynamic Cohort of Italian Patients With Active ITP
Completed NCT00603642 - P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura Phase 3
Not yet recruiting NCT04128358 - Triple Therapy in Patients With Idiopathic Thrombocytopenic Purpura : What is Behind? N/A
Completed NCT00128882 - Treatment of Idiopathic Thrombocytopenic Purpura (ITP) With Subcutaneously Administered Anti-D Phase 2
Completed NCT01525836 - rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP Phase 3
Completed NCT00888901 - Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag Phase 4
Completed NCT00828750 - Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Phase 3
Completed NCT00475423 - A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura. Phase 2
Completed NCT00625443 - Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003 Phase 2
Completed NCT00454857 - Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) N/A
Completed NCT00102323 - AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy Phase 3
Completed NCT05492409 - Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients Phase 3
Terminated NCT01433978 - A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura) Phase 3
Withdrawn NCT01443351 - Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Immune Thrombocytopenia (ITP)
Completed NCT01520909 - Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. Phase 3
Not yet recruiting NCT06287567 - Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP) Phase 4